Prothena Corporation plc - Ordinary Shares (PRTA): Price and Financial Metrics
PRTA Price/Volume Stats
| Current price | $51.43 | 52-week high | $79.65 |
| Prev. close | $52.50 | 52-week low | $28.99 |
| Day low | $51.21 | Volume | 206,810 |
| Day high | $52.42 | Avg. volume | 445,964 |
| 50-day MA | $59.69 | Dividend yield | N/A |
| 200-day MA | $59.23 | Market Cap | 2.75B |
PRTA Stock Price Chart Interactive Chart >
PRTA POWR Grades
- PRTA scores best on the Growth dimension, with a Growth rank ahead of 71.46% of US stocks.
- PRTA's strongest trending metric is Quality; it's been moving down over the last 179 days.
- PRTA's current lowest rank is in the Stability metric (where it is better than 14.41% of US stocks).
PRTA Stock Summary
- PRTA's price/sales ratio is 48.79; that's higher than the P/S ratio of 96.62% of US stocks.
- With a year-over-year growth in debt of -64%, PROTHENA CORP PUBLIC LTD CO's debt growth rate surpasses merely 3.53% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, PROTHENA CORP PUBLIC LTD CO is reporting a growth rate of 3,368.28%; that's higher than 99.62% of US stocks.
- Stocks that are quantitatively similar to PRTA, based on their financial statements, market capitalization, and price volatility, are IONS, MRUS, RNA, CCCC, and ENTA.
- PRTA's SEC filings can be seen here. And to visit PROTHENA CORP PUBLIC LTD CO's official web site, go to www.prothena.com.
PRTA Valuation Summary
- In comparison to the median Healthcare stock, PRTA's price/earnings ratio is 173.39% lower, now standing at -20.
- Over the past 131 months, PRTA's EV/EBIT ratio has gone down 9.7.
Below are key valuation metrics over time for PRTA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PRTA | 2023-09-18 | 48.8 | 4.8 | -20.0 | -14.0 |
| PRTA | 2023-09-15 | 48.7 | 4.8 | -19.9 | -14.0 |
| PRTA | 2023-09-14 | 50.3 | 5.0 | -20.6 | -14.6 |
| PRTA | 2023-09-13 | 50.2 | 5.0 | -20.5 | -14.5 |
| PRTA | 2023-09-12 | 51.5 | 5.1 | -21.0 | -15.0 |
| PRTA | 2023-09-11 | 50.6 | 5.0 | -20.7 | -14.7 |
PRTA Growth Metrics
- Its 4 year revenue growth rate is now at -26.69%.
- The 3 year revenue growth rate now stands at 21953.61%.
- Its 5 year price growth rate is now at -76.52%.
The table below shows PRTA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 5.154 | -126.303 | -156.477 |
| 2022-06-30 | 142.811 | 16.974 | -1.466 |
| 2022-03-31 | 201.57 | 88.856 | 67.42 |
| 2021-12-31 | 200.577 | 92.605 | 66.975 |
| 2021-09-30 | 199.765 | 95.969 | 69.438 |
| 2021-06-30 | 60.748 | -35.545 | -70.386 |
PRTA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PRTA has a Quality Grade of B, ranking ahead of 82.12% of graded US stocks.
- PRTA's asset turnover comes in at 0.448 -- ranking 99th of 682 Pharmaceutical Products stocks.
- RYTM, EVOK, and EVFM are the stocks whose asset turnover ratios are most correlated with PRTA.
The table below shows PRTA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.448 | 1 | 4.191 |
| 2021-06-30 | 0.161 | 1 | -2.858 |
| 2021-03-31 | 0.002 | 1 | -3.400 |
| 2020-12-31 | 0.002 | 1 | -2.721 |
| 2020-09-30 | 0.002 | 1 | -2.229 |
| 2020-06-30 | 0.002 | 1 | -1.819 |
PRTA Price Target
For more insight on analysts targets of PRTA, see our PRTA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $16.40 | Average Broker Recommendation | 1.31 (Strong Buy) |
Prothena Corporation plc - Ordinary Shares (PRTA) Company Bio
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company was founded in 2012 and is based in Dublin, Ireland.
Latest PRTA News From Around the Web
Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.
Pinning Down Prothena Corporation plc's (NASDAQ:PRTA) P/S Is Difficult Right NowYou may think that with a price-to-sales (or "P/S") ratio of 48.7x Prothena Corporation plc ( NASDAQ:PRTA ) is a stock... |
Insider Sell: Chief Medical Officer Hideki Garren Sells 2,000 Shares of Prothena Corp PLCOn September 13, 2023, Hideki Garren, the Chief Medical Officer of Prothena Corp PLC (NASDAQ:PRTA), sold 2,000 shares of the company. |
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's WhyProthena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates. |
Prothena to Participate in Upcoming Healthcare ConferencesDUBLIN, August 31, 2023--Prothena announced that members of its senior management team will participate in upcoming investor conferences. |
Prothena (PRTA) Q2 Earnings and Revenues Miss EstimatesProthena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance. |
PRTA Price Returns
| 1-mo | -10.01% |
| 3-mo | -26.30% |
| 6-mo | 9.26% |
| 1-year | 64.26% |
| 3-year | 402.74% |
| 5-year | 285.53% |
| YTD | -14.64% |
| 2022 | 21.96% |
| 2021 | 311.32% |
| 2020 | -24.13% |
| 2019 | 53.69% |
| 2018 | -72.53% |
Continue Researching PRTA
Want to do more research on Prothena Corp plc's stock and its price? Try the links below:Prothena Corp plc (PRTA) Stock Price | Nasdaq
Prothena Corp plc (PRTA) Stock Quote, History and News - Yahoo Finance
Prothena Corp plc (PRTA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...